Sunitinib is an oral oxindole multitargeted kinase inhibitor that inhibits certain receptor
tyrosine kinases (RTKs). These include vascular endothelial growth factor receptors (VEGFR …

Sunitinib malate is an oral, multitargeted tyrosine kinase inhibitor that targets both
angiogenic pathways (ie, vascular endothelial growth factor receptor and platelet-derived …

Abstract▴ Sunitinib and its active metabolite (SU012662) are selective inhibitors of multiple
receptor tyrosine kinases associated with tumour growth and angiogenesis.▴ The clinical …

Abstract Sunitinib malate (SU11248/Sutent; Pfizer) is a multitargeted tyrosine kinase
inhibitor that has potent anti-angiogenic and antitumour activities. Definitive efficacy has …

Recently, there has been a growing interest in understanding the role of receptor tyrosine
kinases (RTK), such as vascular endothelial growth factor receptor (VEGFR), platelet …

Sunitinib malate is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and
antiangiogenic activities. Sunitinib was recently approved in first-line treatment for patients …

Receptor tyrosine kinases (RTKs) play important roles in the regulation of cellular growth,
and mutated or overexpressed RTKs have been implicated in various human cancers …

The oral multikinase inhibitor sunitinib malate was approved by the US Food and Drug
Administration in January 2006 for use in patients with advanced renal cell carcinoma …

Background: Sunitinib was approved by the US Food and Drug Administration (FDA) on
January 26, 2006, for the treatment of metastatic renal cell carcinoma (mRCC) and …

Sunitinib (SU011248) is an oral small molecular tyrosine kinase inhibitor that exhibits potent
antiangiogenic and antitumor activity. Tyrosine kinase inhibitors such as SU6668 and …